司库奇尤单抗治疗儿童重度斑块状银屑病236周长期安全性与疗效
这项3期试验的扩展期研究评估了司库奇尤单抗在6至<18岁重度斑块状银屑病患者中治疗至236周的长期安全性与疗效。结果显示,第236周时IGA mod 2011 0/1应答率在低剂量组和高剂量组分别为69.4%和79.5%,PASI 75/90/100应答率分别为97.2%/77.8%/50.0%和97.4%/84.6%/69.2%,CDLQI 0/1应答率分别为64.3%和67.7%。最常见不良事件为鼻咽炎、头痛和扁桃体炎,念珠菌感染报告3例,未观察到新的安全性信号。
要点
- 司库奇尤单抗治疗儿童重度斑块状银屑病至236周维持疗效。
- 高剂量组第236周PASI 90和PASI 100应答率分别为84.6%和69.2%。
- 长期安全性良好,最常见不良事件为鼻咽炎、头痛和扁桃体炎。
核心结论
- 司库奇尤单抗在儿童重度斑块状银屑病患者中治疗至236周显示持续疗效和良好安全性。
研究设计与样本
- 3期试验(NCT02471144)扩展期研究,纳入6至<18岁重度慢性斑块状银屑病患者。
- 扩展期(第52-236周)患者接受司库奇尤单抗低剂量或高剂量治疗,剂量根据体重选择。
主要发现
- 第236周IGA mod 2011 0/1应答率:低剂量组69.4%,高剂量组79.5%。
- 第236周PASI 75/90/100应答率:低剂量组97.2%/77.8%/50.0%,高剂量组97.4%/84.6%/69.2%。
- 第236周CDLQI 0/1应答率:低剂量组64.3%,高剂量组67.7%。
- 最常见不良事件为鼻咽炎(EAIR/100 PYs 13.9 [95% CI 10.0, 18.7])、头痛(5.8 [3.7, 8.8])和扁桃体炎(4.7 [2.8, 7.4])。
- 念珠菌感染报告3例。
临床怎么用
- 对于6至<18岁重度斑块状银屑病患者,司库奇尤单抗可作为长期治疗选择,维持皮肤清除和改善生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study (NCT02471144), secukinumab treatment for up to 104 weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis. OBJECTIVES: Final long-term safety and efficacy results of secukinumab through 236 weeks of treatment in paediatric patients with severe chronic plaque psoriasis. METHODS: During the extension period (Weeks 52-236), paediatric patients aged 6 to <18 years with severe chronic plaque psoriasis received either 'Any secukinumab' low dose (LD; patients receiving secukinumab LD up to Week 52; patients on placebo who transitioned to secukinumab LD) or 'Any secukinumab' high dose (HD; patients receiving secukinumab HD up to Week 52 and patients on placebo who transitioned to secukinumab HD). Assessments included Psoriasis Area and Severity Index (PASI) 75/90/100 responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, relapse, rebound, Children's Dermatology Life Quality Index (CDLQI) score, CDLQI 0/1 response and long-term safety up to Week 236. RESULTS: Secukinumab maintained efficacy through 236 weeks of treatment, with consistent responses observed in most assessments across both dose groups. At Week 236, the responder rate for IGA mod 2011 0/1 was 69.4% ('Any secukinumab' LD) and 79.5% ('Any secukinumab' HD); the PASI 75/90/100 responses were 97.2%/77.8%/50.0% ('Any secukinumab' LD) and 97.4%/84.6%/69.2% ('Any secukinumab' HD). CDLQI 0/1 responses remained consistent in both dose groups and were maintained up to Week 236 ('Any secukinumab' LD: 64.3%; 'Any secukinumab' HD: 67.7%). The most common adverse events were nasopharyngitis (EAIR/100 PYs [95% CI]:13.9 [10.0, 18.7]), headache (5.8 [3.7, 8.8]) and tonsillitis (4.7 [2.8, 7.4]). Candida infections were reported in 3 patients. CONCLUSIONS: These findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236-week treatment period. Plaque psoriasis is a long‐term skin disease that causes red, scaly patches and affects approximately 2 in 100 children globally. It can significantly impact children’s comfort and daily lives. Secukinumab is a medicine specifically designed to block ‘interleukin‐17A’, a protein found in high amounts in people with plaque psoriasis. We conducted an international multicentre trial to test the long‐term safety and effectiveness of secukinumab in children aged 6–17 years with severe plaque psoriasis. In this clinical study, 114 participants received low or high doses of secukinumab via a subcutaneous injection for up to 236 weeks (about 4.5 years), based on body weight (≥50 kg: 150 mg [low dose] or 300 mg [high dose]; 25 to < 50 kg: 75 mg [low dose] or 150 mg [high dose]; <25 kg: 75 mg for both doses). We evaluated whether secukinumab could reduce symptoms of plaque psoriasis using doctor assessments and a quality‐of‐life questionnaire, which measures the impact of skin disease on participants’ daily lives. We also monitored for any adverse reactions (undesired effects that may be related to a medication) related to secukinumab. The results showed that both doses helped most children achieve major improvement in symptoms by the end of the 236‐week treatment, with many achieving and maintaining clear skin. No new or unexpected safety concerns were observed. These results suggest that secukinumab works well and is safe as a long‐term treatment option for children with severe plaque psoriasis, offering lasting skin improvement and a better quality of life.
引用
- Kaszuba A, Papanastasiou P, Krasowska D, et al. Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results. J Eur Acad Dermatol Venereol. 2025. PMID: 41239909. doi:10.1111/jdv.70155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。